USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy (8.3)Geriatric Use: Assess renal function more frequently (8.5)Hepatic Impairment: Avoid use in patients with hepatic impairment (8.7). Females and Males of Reproductive Potential: Advise premenopausal females of the potential for an unintended pregnancy (8.3). Geriatric Use: Assess renal function more frequently (8.5). Hepatic Impairment: Avoid use in patients with hepatic impairment (8.7). 8.1 Pregnancy. Risk SummaryThe limited data with JENTADUETO and linagliptin use in pregnant women are not sufficient to inform JENTADUETO-associated or linagliptin-associated risk for major birth defects and miscarriage. Published studies with metformin use during pregnancy have not reported clear association with metformin and major birth defect or miscarriage risk [see Data]. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]. In animal reproduction studies, no adverse developmental effects were observed when the combination of linagliptin and metformin was administered to pregnant rats during the period of organogenesis at doses similar to the maximum recommended clinical dose, based on exposure [see Data].The estimated background risk of major birth defects is to 10% in women with pre-gestational diabetes with HbA1c>7 and has been reported to be as high as 20 to 25% in women with HbA1c>10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively. Clinical Considerations. Disease-associated maternal and/or embryo/fetal riskPoorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.. Data. Human DataPublished data from postmarketing studies have not reported clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups.. Animal DataLinagliptin and metformin, the components of JENTADUETO, were coadministered to pregnant Wistar Han rats during the period of organogenesis. No adverse developmental outcome was observed at doses similar to the maximum recommended clinical dose, based on exposure. At higher doses associated with maternal toxicity, the metformin component of the combination was associated with an increased incidence of fetal rib and scapula malformations at >=9-times 2000 mg clinical dose, based on exposure. LinagliptinNo adverse developmental outcome was observed when linagliptin was administered to pregnant Wistar Han rats and Himalayan rabbits during the period of organogenesis at doses up to 240 mg/kg and 150 mg/kg, respectively. These doses represent approximately 943-times (rats) and 1943-times (rabbits) the mg clinical dose, based on exposure. No adverse functional, behavioral, or reproductive outcome was observed in offspring following administration of linagliptin to Wistar Han rats from gestation day to lactation day 21 at dose 49-times the mg clinical dose, based on exposure. Metformin HydrochlorideMetformin hydrochloride did not cause adverse developmental effects when administered to pregnant rabbits up to 600 mg/kg/day during the period of organogenesis. This represents an exposure of approximately 6-times clinical dose of 2000 mg, based on body surface area.. 8.2 Lactation. Risk SummaryThere is no information regarding the presence of JENTADUETO or linagliptin in human milk, the effects on the breastfed infant, or the effects on milk production. However, linagliptin is present in rat milk. Limited published studies report that metformin is present in human milk [see Data]. However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for JENTADUETO and any potential adverse effects on the breastfed child from JENTADUETO or from the underlying maternal condition.. Data Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage and milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.. 8.3 Females and Males of Reproductive Potential. Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin may result in ovulation in some anovulatory women.. 8.4 Pediatric Use. Safety and effectiveness of JENTADUETO in pediatric patients under 18 years of age have not been established.. 8.5 Geriatric Use. Linagliptin is minimally excreted by the kidney; however, metformin is substantially excreted by the kidney [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. LinagliptinIn the 15 type diabetes studies with linagliptin, 1085 linagliptin-treated patients were 65 years of age and older (including 131 linagliptin-treated patients 75 years of age and older). Of these 15 studies, 12 were double-blind placebo-controlled. In these 12 studies, 591 linagliptin-treated patients were 65 years of age and older (including 82 linagliptin-treated patients 75 years of age and older). In these linagliptin studies, no overall differences in safety or effectiveness of linagliptin were observed between geriatric patients and younger adult patients.. MetforminControlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients [see Contraindications (4), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)]. 8.6 Renal Impairment. Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. JENTADUETO is contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)]. If JENTADUETO is discontinued due to evidence of renal impairment, linagliptin may be continued as single entity tablet at the same total daily dose of mg. No dose adjustment of linagliptin is recommended in patients with renal impairment.In the linagliptin treatment arm of the CARMELINA trial [see Clinical Studies (14.2)], 2200 (63%) patients had renal impairment (eGFR <60 mL/min/1.73 m2). Approximately 20% of the population had eGFR >=45 to <60 mL/min/1.73 m2, 28% of the population had eGFR >=30 to <45 mL/min/1.73 m2 and 15% had eGFR <30 mL/min/1.73 m2. The overall incidence of adverse reactions were generally similar between the linagliptin and placebo treatment arms. 8.7 Hepatic Impairment. Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. JENTADUETO is not recommended in patients with hepatic impairment [see Warnings and Precautions (5.1)].

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Lactic acidosis: See boxed warning (5.1)Pancreatitis: There have been reports of acute pancreatitis, including fatal pancreatitis. If pancreatitis is suspected, promptly discontinue JENTADUETO. (5.2)Heart failure: Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of JENTADUETO in patients who have known risk factors for heart failure. Monitor for signs and symptoms. (5.3)Hypoglycemia: When used with an insulin secretagogue (e.g., sulfonylurea (SU)) or insulin, consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia (5.4)Hypersensitivity reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, and exfoliative skin conditions) have occurred with JENTADUETO. If hypersensitivity reactions occur discontinue JENTADUETO, treat promptly, and monitor until signs and symptoms resolve. (5.5)Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. Monitor hematologic parameters annually. (5.6)Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as possible cause for severe joint pain and discontinue drug if appropriate. (5.7)Bullous pemphigoid: There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue JENTADUETO. (5.8). Lactic acidosis: See boxed warning (5.1). Pancreatitis: There have been reports of acute pancreatitis, including fatal pancreatitis. If pancreatitis is suspected, promptly discontinue JENTADUETO. (5.2). Heart failure: Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of JENTADUETO in patients who have known risk factors for heart failure. Monitor for signs and symptoms. (5.3). Hypoglycemia: When used with an insulin secretagogue (e.g., sulfonylurea (SU)) or insulin, consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia (5.4). Hypersensitivity reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, and exfoliative skin conditions) have occurred with JENTADUETO. If hypersensitivity reactions occur discontinue JENTADUETO, treat promptly, and monitor until signs and symptoms resolve. (5.5). Vitamin B12 deficiency: Metformin may lower vitamin B12 levels. Monitor hematologic parameters annually. (5.6). Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as possible cause for severe joint pain and discontinue drug if appropriate. (5.7). Bullous pemphigoid: There have been reports of bullous pemphigoid requiring hospitalization. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue JENTADUETO. (5.8). 5.1 Lactic Acidosis. MetforminThere have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate pyruvate ratio; metformin plasma levels generally >5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase risk of lactic acidosis, especially in patients at risk. If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in hospital setting, along with immediate discontinuation of JENTADUETO. In JENTADUETO-treated patients with diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable, with clearance of up to 170 mL/min under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery. Educate patients and their families about the symptoms of lactic acidosis and if these symptoms occur instruct them to discontinue JENTADUETO and report these symptoms to their healthcare provider.For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:. Renal Impairment: The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment. The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patients renal function include [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]: Before initiating JENTADUETO, obtain an estimated glomerular filtration rate (eGFR). JENTADUETO is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2 [see Contraindications (4)]. Initiation of JENTADUETO is not recommended in patients with eGFR between 30 45 mL/min/1.73 m2. Obtain an eGFR at least annually in all patients taking JENTADUETO. In patients at increased risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently. In patients taking JENTADUETO whose eGFR later falls below 45 mL/min/1.73 m2, assess the benefit and risk of continuing therapy.. Before initiating JENTADUETO, obtain an estimated glomerular filtration rate (eGFR). JENTADUETO is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m2 [see Contraindications (4)]. Initiation of JENTADUETO is not recommended in patients with eGFR between 30 45 mL/min/1.73 m2. Obtain an eGFR at least annually in all patients taking JENTADUETO. In patients at increased risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently. In patients taking JENTADUETO whose eGFR later falls below 45 mL/min/1.73 m2, assess the benefit and risk of continuing therapy.. Drug Interactions: The concomitant use of JENTADUETO with specific drugs may increase the risk of metformin-associated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation [see Drug Interactions (7.1)]. Therefore, consider more frequent monitoring of patients. Age 65 or Greater: The risk of metformin-associated lactic acidosis increases with the patients age because elderly patients have greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients [see Use in Specific Populations (8.5)].. Radiological Studies with Contrast: Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop JENTADUETO at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart JENTADUETO if renal function is stable.. Surgery and Other Procedures: Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension and renal impairment. JENTADUETO should be temporarily discontinued while patients have restricted food and fluid intake.. Hypoxic States: Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur, discontinue JENTADUETO.. Excessive Alcohol Intake: Alcohol potentiates the effect of metformin on lactate metabolism and this may increase the risk of metformin-associated lactic acidosis. Warn patients against excessive alcohol intake while receiving JENTADUETO.. Hepatic Impairment: Patients with hepatic impairment have developed cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of JENTADUETO in patients with clinical or laboratory evidence of hepatic disease.. 5.2 Pancreatitis. Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with linagliptin. In the CARMELINA trial [see Clinical Studies (14.2)], acute pancreatitis was reported in (0.3%) patients treated with linagliptin and in (0.1%) patients treated with placebo. Two patients treated with linagliptin in the CARMELINA trial had acute pancreatitis with fatal outcome. There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients treated with linagliptin.Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JENTADUETO and initiate appropriate management. It is unknown whether patients with history of pancreatitis are at increased risk for the development of pancreatitis while using JENTADUETO.. 5.3 Heart Failure. An association between DPP-4 inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type diabetes mellitus and atherosclerotic cardiovascular disease. Consider the risks and benefits of JENTADUETO prior to initiating treatment in patients at risk for heart failure, such as those with prior history of heart failure and history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of JENTADUETO.. 5.4 Use with Medications Known to Cause Hypoglycemia. Insulin secretagogues and insulin are known to cause hypoglycemia. The use of linagliptin in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin was associated with higher rate of hypoglycemia compared with placebo in clinical trials [see Adverse Reactions (6.1)]. Metformin may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia when used in combination with JENTADUETO [see Drug Interactions (7.3)]. 5.5 Hypersensitivity Reactions. There have been postmarketing reports of serious hypersensitivity reactions in patients treated with linagliptin (one of the components of JENTADUETO). These reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred predominantly within the first months after initiation of treatment with linagliptin, with some reports occurring after the first dose. If serious hypersensitivity reaction is suspected, discontinue JENTADUETO, assess for other potential causes for the event, and institute alternative treatment for diabetes.Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. Use caution in patient with history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JENTADUETO.. 5.6 Vitamin B12 Levels. In controlled, 29-week clinical trials of metformin, decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of metformin-treated patients. Such decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, may be associated with anemia or neurologic manifestations. This risk may be more relevant to patients receiving long-term treatment with metformin, and adverse hematologic and neurologic reactions have been reported postmarketing. The decrease in vitamin B12 levels appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation. Measurement of hematologic parameters on an annual basis and routine serum vitamin B12 measurement at 2- to 3-year intervals is advised in patients on JENTADUETO and any apparent abnormalities should be appropriately investigated and managed. Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels.. 5.7 Severe and Disabling Arthralgia. There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. subset of patients experienced recurrence of symptoms when restarting the same drug or different DPP-4 inhibitor. Consider DPP-4 inhibitors as possible cause for severe joint pain and discontinue drug if appropriate.. 5.8 Bullous Pemphigoid. Bullous pemphigoid was reported in (0.2%) patients treated with linagliptin compared to none in patients treated with placebo in the CARMELINA trial [see Clinical Studies (14.2)], and of these patients were hospitalized due to bullous pemphigoid. Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving JENTADUETO. If bullous pemphigoid is suspected, JENTADUETO should be discontinued and referral to dermatologist should be considered for diagnosis and appropriate treatment.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following serious adverse reactions are described below or elsewhere in the prescribing information:Lactic Acidosis [see Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Heart Failure [see Warnings and Precautions (5.3)] Use with Medications Known to Cause Hypoglycemia [see Warnings and Precautions (5.4)] Hypersensitivity Reactions [see Warnings and Precautions (5.5)] Vitamin B12 Levels [see Warnings and Precautions (5.6)] Severe and Disabling Arthralgia [see Warnings and Precautions (5.7)] Bullous Pemphigoid [see Warnings and Precautions (5.8)] Lactic Acidosis [see Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Heart Failure [see Warnings and Precautions (5.3)] Use with Medications Known to Cause Hypoglycemia [see Warnings and Precautions (5.4)] Hypersensitivity Reactions [see Warnings and Precautions (5.5)] Vitamin B12 Levels [see Warnings and Precautions (5.6)] Severe and Disabling Arthralgia [see Warnings and Precautions (5.7)] Bullous Pemphigoid [see Warnings and Precautions (5.8)] Adverse reactions reported in >=5% of patients treated with JENTADUETO and more commonly than in patients treated with placebo are nasopharyngitis and diarrhea (6.1)To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or 1-800-459-9906 TTY, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.. Linagliptin/MetforminThe safety of concomitantly administered linagliptin (daily dose mg) and metformin (mean daily dose of approximately 1800 mg) has been evaluated in 2816 patients with type diabetes mellitus treated for >=12 weeks in clinical trials. Three placebo-controlled studies with linagliptin metformin were conducted: studies were 24 weeks in duration, study was 12 weeks in duration. In the placebo-controlled clinical studies, adverse reactions which occurred in >=5% of patients receiving linagliptin metformin (n=875) and were more common than in patients given placebo metformin (n=539) included nasopharyngitis (5.7% vs 4.3%).In 24-week factorial design study, adverse reactions reported in >=5% of patients receiving linagliptin metformin and were more common than in patients given placebo are shown in Table 1.Table 1Adverse Reactions Reported in >=5% of Patients Treated with Linagliptin Metformin and Greater than with Placebo in 24-week Factorial-Design StudyPlacebon=72Linagliptin Monotherapyn=142Metformin Monotherapyn=291Combination of Linagliptin with Metforminn=286n (%)n (%)n (%)n (%)Nasopharyngitis1 (1.4)8 (5.6)8 (2.7)18 (6.3)Diarrhea2 (2.8)5 (3.5)11 (3.8)18 (6.3)Other adverse reactions reported in clinical studies with treatment of linagliptin metformin were hypersensitivity (e.g., urticaria, angioedema, or bronchial hyperreactivity), cough, decreased appetite, nausea, vomiting, pruritus, and pancreatitis.. LinagliptinAdverse reactions reported in >=2% of patients treated with linagliptin mg and more commonly than in patients treated with placebo included: nasopharyngitis (7.0% vs 6.1%), diarrhea (3.3% vs 3.0%), and cough (2.1% vs 1.4%).Rates for other adverse reactions for linagliptin mg vs placebo when linagliptin was used in combination with specific anti-diabetic agents were: urinary tract infection (3.1% vs 0%) and hypertriglyceridemia (2.4% vs 0%) when linagliptin was used as add-on to sulfonylurea; hyperlipidemia (2.7% vs 0.8%) and weight increased (2.3% vs 0.8%) when linagliptin was used as add-on to pioglitazone; and constipation (2.1% vs 1%) when linagliptin was used as add-on to basal insulin therapy.Other adverse reactions reported in clinical studies with treatment of linagliptin monotherapy were hypersensitivity (e.g., urticaria, angioedema, localized skin exfoliation, or bronchial hyperreactivity) and myalgia. In the clinical trial program, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure while being treated with linagliptin compared with 3.7 cases per 10,000 patient year exposure while being treated with comparator (placebo and active comparator, sulfonylurea). Three additional cases of pancreatitis were reported following the last administered dose of linagliptin.. MetforminThe most common adverse reactions due to initiation of metformin are diarrhea, nausea/vomiting, flatulence, asthenia, indigestion, abdominal discomfort, and headache.. Hypoglycemia. Linagliptin/MetforminIn 24-week factorial design study, hypoglycemia was reported in (1.4%) of 286 subjects treated with linagliptin metformin, (2.1%) of 291 subjects treated with metformin, and (1.4%) of 72 subjects treated with placebo. The incidence of hypoglycemia with plasma glucose <54 mg/dL was 8.1% in the linagliptin group (N=792) compared to 5.3% in the placebo group (N=263) when administered in combination with metformin and sulfonylurea in 24-week study.. LinagliptinThe incidence of severe hypoglycemia (requiring assistance) was 1.7% in the linagliptin group (N=631) compared to 1.1% in the placebo group (N=630) when administered in combination with basal insulin in 52 week study.. Laboratory Tests. Linagliptin. Increase in Uric Acid: Changes in laboratory values that occurred more frequently in the linagliptin group and >=1% more than in the placebo group were increases in uric acid (1.3% in the placebo group, 2.7% in the linagliptin group).. Increase in Lipase: In placebo-controlled clinical trial with linagliptin in type diabetes mellitus patients with micro- or macroalbuminuria, mean increase of 30% in lipase concentrations from baseline to 24 weeks was observed in the linagliptin arm compared to mean decrease of 2% in the placebo arm. Lipase levels above times upper limit of normal were seen in 8.2% compared to 1.7% patients in the linagliptin and placebo arms, respectively. Increase in Amylase: In cardiovascular safety study comparing linagliptin versus glimepiride in patients with type diabetes mellitus, amylase levels above times upper limit of normal were seen in 1.0% compared to 0.5% of patients in the linagliptin and glimepiride arms, respectively.The clinical significance of elevations in lipase and amylase with linagliptin is unknown in the absence of potential signs and symptoms of pancreatitis [see Warnings and Precautions (5.2)]. Metformin. Decrease in Vitamin B12 Absorption: Treatment with metformin has been associated with decrease in vitamin B12 absorption which may result in clinically significant vitamin B12 deficiency (e.g., megaloblastic anemia) [see Warnings and Precautions (5.6)].. 6.2 Postmarketing Experience. The following adverse reactions have been identified during postapproval use. Because these reactions are reported voluntarily from population of uncertain size, it is generally not possible to reliably estimate their frequency or establish causal relationship to drug exposure.. LinagliptinAcute pancreatitis, including fatal pancreatitis [see Indications and Usage (1)] Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditionsSevere and disabling arthralgiaBullous pemphigoidRashMouth ulceration, stomatitisRhabdomyolysis. Acute pancreatitis, including fatal pancreatitis [see Indications and Usage (1)] Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions. Severe and disabling arthralgia. Bullous pemphigoid. Rash. Mouth ulceration, stomatitis. Rhabdomyolysis. MetforminCholestatic, hepatocellular, and mixed hepatocellular liver injury. Cholestatic, hepatocellular, and mixed hepatocellular liver injury.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. JENTADUETOJENTADUETO combines antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type diabetes mellitus: linagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, member of the biguanide class.. LinagliptinLinagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in reduction in hepatic glucose output. MetforminMetformin is an antihyperglycemic agent which improves glucose tolerance in patients with type diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.. 12.2 Pharmacodynamics. LinagliptinLinagliptin binds to DPP-4 in reversible manner and increases the concentrations of incretin hormones. Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion, thus resulting in better regulation of the glucose homeostasis. Linagliptin binds selectively to DPP-4 and selectively inhibits DPP-4, but not DPP-8 or DPP-9 activity in vitro at concentrations approximating therapeutic exposures.. Cardiac ElectrophysiologyIn randomized, placebo-controlled, active-comparator, 4-way crossover study, 36 healthy subjects were administered single oral dose of linagliptin mg, linagliptin 100 mg (20 times the recommended dose), moxifloxacin, and placebo. No increase in QTc was observed with either the recommended dose of mg or the 100-mg dose. At the 100-mg dose, peak linagliptin plasma concentrations were approximately 38-fold higher than the peak concentrations following 5-mg dose.. 12.3 Pharmacokinetics. JENTADUETOThe results of bioequivalence study in healthy subjects demonstrated that JENTADUETO (linagliptin/metformin hydrochloride) 2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 mg/1000 mg combination tablets are bioequivalent to coadministration of corresponding doses of linagliptin and metformin as individual tablets. Administration of linagliptin 2.5 mg/metformin hydrochloride 1000 mg fixed-dose combination with food resulted in no change in overall exposure of linagliptin. There was no change in metformin AUC; however, mean peak serum concentration of metformin was decreased by 18% when administered with food. delayed time-to-peak serum concentrations by hours was observed for metformin under fed conditions. These changes are not likely to be clinically significant.. Absorption. LinagliptinThe absolute bioavailability of linagliptin is approximately 30%. Following oral administration, plasma concentrations of linagliptin decline in at least biphasic manner with long terminal half-life (>100 hours), related to the saturable binding of linagliptin to DPP-4. However, the prolonged elimination does not contribute to the accumulation of the drug. The effective half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of linagliptin mg, is approximately 12 hours. After once-daily dosing, steady-state plasma concentrations of linagliptin mg are reached by the third dose, and Cmax and AUC increased by factor of 1.3 at steady-state compared with the first dose. Plasma AUC of linagliptin increased in less than dose-proportional manner in the dose range of to 10 mg. The pharmacokinetics of linagliptin is similar in healthy subjects and in patients with type diabetes. MetforminThe absolute bioavailability of metformin hydrochloride 500 mg tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin tablets 500 mg to 1500 mg, and 850 mg to 2550 mg, indicate that there is lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Distribution. LinagliptinThe mean apparent volume of distribution at steady-state following single intravenous dose of linagliptin mg to healthy subjects is approximately 1110 L, indicating that linagliptin extensively distributes to the tissues. Plasma protein binding of linagliptin is concentration-dependent decreasing from about 99% at nmol/L to 75% to 89% at >=30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin. At high concentrations, where DPP-4 is fully saturated, 70% to 80% of linagliptin remains bound to plasma proteins and 20% to 30% is unbound in plasma. Plasma binding is not altered in patients with renal or hepatic impairment.. MetforminThe apparent volume of distribution (V/F) of metformin following single oral doses of immediate-release metformin hydrochloride tablets 850 mg averaged 654+-358 L. Metformin is negligibly bound to plasma proteins, in contrast to SUs, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as function of time. At usual clinical doses and dosing schedules of metformin tablets, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally <1 mcg/mL. During controlled clinical trials of metformin, maximum metformin plasma levels did not exceed mcg/mL, even at maximum doses.. Elimination. LinagliptinLinagliptin has terminal half-life of about 200 hours at steady-state, though the accumulation half-life is about 11 hours. Renal clearance at steady-state was approximately 70 mL/min.. MetforminMetformin has plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be compartment of distribution.. Metabolism. LinagliptinFollowing oral administration, the majority (about 90%) of linagliptin is excreted unchanged, indicating that metabolism represents minor elimination pathway. small fraction of absorbed linagliptin is metabolized to pharmacologically inactive metabolite, which shows steady-state exposure of 13.3% relative to linagliptin.. MetforminIntravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.. Excretion. LinagliptinFollowing administration of an oral [14C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated via the enterohepatic system (80%) or urine (5%) within days of dosing.. MetforminRenal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be compartment of distribution.. Specific Populations. Renal Impairment JENTADUETO: Studies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in renally impaired patients have not been performed [see Contraindications (4) and Warnings and Precautions (5.1)]. Linagliptin: Under steady-state conditions, linagliptin exposure in patients with mild renal impairment was comparable to healthy subjects. In patients with moderate renal impairment under steady-state conditions, mean exposure of linagliptin increased (AUC,ss by 71% and Cmax by 46%) compared with healthy subjects. This increase was not associated with prolonged accumulation half-life, terminal half-life, or an increased accumulation factor. Renal excretion of linagliptin was below 5% of the administered dose and was not affected by decreased renal function. Patients with type diabetes mellitus and severe renal impairment showed steady-state exposure approximately 40% higher than that of patients with type diabetes mellitus and normal renal function (increase in AUC by 42% and Cmax by 35%). For both type diabetes mellitus groups, renal excretion was below 7% of the administered dose. Metformin: In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased [see Contraindications (4) and Warnings and Precautions (5.1)].. Hepatic Impairment. JENTADUETO: Studies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in hepatically impaired patients have not been performed [see Warnings and Precautions (5.1)].. Linagliptin: In patients with mild hepatic impairment (Child-Pugh class A) steady-state exposure (AUC,ss) of linagliptin was approximately 25% lower and Cmax,ss was approximately 36% lower than in healthy subjects. In patients with moderate hepatic impairment (Child-Pugh class B), AUCss of linagliptin was about 14% lower and Cmax,ss was approximately 8% lower than in healthy subjects. Patients with severe hepatic impairment (Child-Pugh class C) had comparable exposure of linagliptin in terms of AUC0-24 and approximately 23% lower Cmax compared with healthy subjects. Reductions in the pharmacokinetic parameters seen in patients with hepatic impairment did not result in reductions in DPP-4 inhibition.. Metformin hydrochloride: No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment. Body Mass Index (BMI)/Weight. Linagliptin: BMI/Weight had no clinically meaningful effect on the pharmacokinetics of linagliptin based on population pharmacokinetic analysis.. Gender. Linagliptin: Gender had no clinically meaningful effect on the pharmacokinetics of linagliptin based on population pharmacokinetic analysis.. Metformin hydrochloride: Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type diabetes mellitus when analyzed according to gender. Similarly, in controlled clinical studies in patients with type diabetes mellitus, the antihyperglycemic effect of metformin was comparable in males and females.. Geriatric. JENTADUETO: Studies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in geriatric patients have not been performed [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5)]. Linagliptin: Age did not have clinically meaningful impact on the pharmacokinetics of linagliptin based on population pharmacokinetic analysis.. Metformin hydrochloride: Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared with healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by change in renal function.. PediatricStudies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in pediatric patients have not yet been performed.. Race. Linagliptin: Race had no clinically meaningful effect on the pharmacokinetics of linagliptin based on available pharmacokinetic data, including subjects of White, Hispanic, Black, and Asian racial groups.. Metformin hydrochloride: No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type diabetes mellitus, the antihyperglycemic effect was comparable in Caucasians (n=249), Blacks (n=51), and Hispanics (n=24).. Drug InteractionsPharmacokinetic drug interaction studies with JENTADUETO have not been performed; however, such studies have been conducted with the individual components of JENTADUETO (linagliptin and metformin hydrochloride).. Linagliptin. In vitro Assessment of Drug InteractionsLinagliptin is weak to moderate inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes and is not an inducer of CYP isozymes, including CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 4A11.Linagliptin is P-glycoprotein (P-gp) substrate, and inhibits P-gp mediated transport of digoxin at high concentrations. Based on these results and in vivo drug interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates at therapeutic concentrations.. In vivo Assessment of Drug InteractionsStrong inducers of CYP3A4 or P-gp (e.g., rifampin) decrease exposure to linagliptin to subtherapeutic and likely ineffective concentrations [see Drug Interactions (7)]. In vivo studies indicated evidence of low propensity for causing drug interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-gp, and OCT.Table 2Effect of Coadministered Drugs on Systemic Exposure of LinagliptinCoadministered DrugDosing of Coadministered DrugDosing of LinagliptinGeometric Mean Ratio(ratio with/without coadministered drug)No effect=1.0AUC+ Cmax Multiple dose (steady-state) unless otherwise notedFor information regarding clinical recommendations [see Drug Interactions (7.2)]. Single dose+AUC AUC(0 to 24 hours) for single-dose treatments and AUC AUC(TAU) for multiple-dose treatmentsQD=once dailyBID=twice dailyTID=three times dailyMetformin 850 mg TID10 mg QD1.201.03Glyburide1.75 mg mg QD1.021.01Pioglitazone45 mg QD10 mg QD1.131.07Ritonavir200 mg BID5 mg 2.012.96Rifampin600 mg QD5 mg QD0.600.56Table 3Effect of Linagliptin on Systemic Exposure of Coadministered DrugsCoadministered DrugDosing of Coadministered DrugDosing of LinagliptinGeometric Mean Ratio(ratio with/without coadministered drug)No effect=1.0AUC+ Cmax Multiple dose (steady-state) unless otherwise notedSingle dose+AUC AUC(INF) for single-dose treatments and AUC AUC(TAU) for multiple-dose treatmentsAUC=AUC(0-168) and Cmax=Emax for pharmacodynamic end pointsINR=International Normalized RatioPT=Prothrombin TimeQD=once dailyTID=three times dailyMetformin 850 mg TID10 mg QDmetformin1.010.89Glyburide1.75 mg mg QDglyburide0.860.86Pioglitazone45 mg QD10 mg QDpioglitazone0.940.86metabolite M-III0.980.96metabolite M-IV1.041.05Digoxin0.25 mg QD5 mg QDdigoxin1.020.94Simvastatin40 mg QD10 mg QDsimvastatin1.341.10simvastatin acid1.331.21Warfarin10 mg mg QDR-warfarin0.991.00S-warfarin1.031.01INR0.931.04PT1.031.15Ethinylestradiol and levonorgestrelethinylestradiol 0.03 mg and levonorgestrel 0.150 mg QD5 mg QDethinylestradiol1.011.08levonorgestrel1.091.13. Metformin hydrochlorideTable 4Effect of Coadministered Drug on Plasma Metformin Systemic Exposure Coadministered DrugDosing of Coadministered DrugDosing of MetforminGeometric Mean Ratio(ratio with/without coadministered drug)No effect=1.0AUC+ Cmax All metformin and coadministered drugs were given as single doses+AUC=AUC(INF)Ratio of arithmetic meansAt steady-state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC AUC(0-12 hours)Glyburide5 mg850 mgmetformin0.910.93Furosemide40 mg850 mgmetformin1.091.22Nifedipine10 mg850 mgmetformin1.161.21Propranolol40 mg850 mgmetformin0.900.94Ibuprofen400 mg850 mgmetformin1.051.07Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination[see Drug Interactions (7.1)]. Cimetidine400 mg850 mgmetformin1.401.61Carbonic anhydrase inhibitors may cause metabolic acidosis [see Drug Interactions (7.1)].Topiramate100 mg500 mgmetformin1.251.17Table 5Effect of Metformin on Coadministered Drug Systemic ExposureCoadministered DrugDosing of Coadministered DrugDosing of MetforminGeometric Mean Ratio(ratio with/without metformin)No effect=1.0AUC+ Cmax All metformin and coadministered drugs were given as single doses+AUC=AUC(INF) unless otherwise notedRatio of arithmetic means, p-value of difference <0.05AUC(0-24 hours) reportedRatio of arithmetic meansGlyburide5 mg850 mgglyburide0.780.63Furosemide40 mg850 mgfurosemide0.870.69Nifedipine10 mg850 mgnifedipine1.101.08Propranolol40 mg850 mgpropranolol1.011.02Ibuprofen400 mg850 mgibuprofen0.971.01Cimetidine400 mg850 mgcimetidine0.951.01.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. The coadministration of linagliptin and metformin has been studied in patients with type diabetes mellitus inadequately controlled on diet and exercise and in combination with sulfonylurea.There have been no clinical efficacy studies conducted with JENTADUETO; however, bioequivalence of JENTADUETO to linagliptin and metformin coadministered as individual tablets was demonstrated in healthy subjects. 14.1 Glycemic Control Trials. Initial Combination Therapy with Linagliptin and MetforminA total of 791 patients with type diabetes mellitus and inadequate glycemic control on diet and exercise participated in the 24-week, randomized, double-blind, portion of this placebo-controlled factorial study designed to assess the efficacy of linagliptin as initial therapy with metformin. Patients on an antihyperglycemic agent (52%) underwent drug washout period of weeks duration. After the washout period and after completing 2-week single-blind placebo run-in period, patients with inadequate glycemic control (A1C >=7.0% to <=10.5%) were randomized. Patients with inadequate glycemic control (A1C >=7.5% to <11.0%) not on antihyperglycemic agents at study entry (48%) immediately entered the 2-week single-blind placebo run-in period and then were randomized. Randomization was stratified by baseline A1C (<8.5% vs >=8.5%) and use of prior oral antidiabetic drug (none vs monotherapy). Patients were randomized in 1:2:2:2:2:2 ratio to either placebo or one of active-treatment arms. Approximately equal numbers of patients were randomized to receive initial therapy with mg of linagliptin once daily, 500 mg or 1000 mg of metformin twice daily, or 2.5 mg of linagliptin twice daily in combination with 500 mg or 1000 mg of metformin twice daily. Patients who failed to meet specific glycemic goals during the study were treated with sulfonylurea, thiazolidinedione, or insulin rescue therapy.Initial therapy with the combination of linagliptin and metformin provided significant improvements in A1C, and fasting plasma glucose (FPG) compared to placebo, to metformin alone, and to linagliptin alone (Table 6, Figure 1). The adjusted mean treatment difference in A1C from baseline to week 24 (LOCF) was -0.5% (95% CI -0.7, -0.3; p<0.0001) for linagliptin 2.5 mg/metformin 1000 mg twice daily compared to metformin 1000 mg twice daily; -1.1% (95% CI -1.4, -0.9; p<0.0001) for linagliptin 2.5 mg/metformin 1000 mg twice daily compared to linagliptin mg once daily; -0.6% (95% CI -0.8, -0.4; p<0.0001) for linagliptin 2.5 mg/metformin 500 mg twice daily compared to metformin 500 mg twice daily; and -0.8% (95% CI -1.0, -0.6; p<0.0001) for linagliptin 2.5 mg/metformin 500 mg twice daily compared to linagliptin mg once daily. Lipid effects were generally neutral. No meaningful change in body weight was noted in any of the treatment groups.Table 6Glycemic Parameters at Final Visit (24-Week Study) for Linagliptin and Metformin, Alone and in Combination in Randomized Patients with Type Diabetes Mellitus Inadequately Controlled on Diet and ExercisePlaceboLinagliptin mg Once DailyMetformin 500 mg Twice DailyLinagliptin 2.5 mgTwice Daily Metformin 500 mgTwice DailyMetformin 1000 mg Twice DailyLinagliptin 2.5 mgTwice Daily Metformin 1000 mgTwice DailyTotal daily dose of linagliptin is equal to mgFull analysis population using last observation on studyMetformin 500 mg twice daily, n=140; Linagliptin 2.5 mg twice daily Metformin 500 mg twice daily, n=136; Metformin 1000 mg twice daily, n=137; Linagliptin 2.5 mg twice daily Metformin 1000 mg twice daily, n=138HbA1c: ANCOVA model included treatment and number of prior OADs as class-effects, as well as baseline HbA1c as continuous covariates. FPG: ANCOVA model included treatment and number of prior OADs as class-effects, as well as baseline HbA1c and baseline FPG as continuous covariates.A1C (%)Number of patientsn=65n=135n=141n=137n=138n=140Baseline (mean)8.78.78.78.78.58.7Change from baseline (adjusted mean)0.1-0.5-0.6-1.2-1.1-1.6Difference from placebo (adjusted mean) (95% CI)---0.6 (-0.9, -0.3)-0.8 (-1.0, -0.5)-1.3 (-1.6, -1.1)-1.2 (-1.5, -0.9)-1.7 (-2.0, -1.4)Patients [n (%)] achieving A1C <7%7 (10.8)14 (10.4)26 (18.6)41 (30.1)42 (30.7)74 (53.6)Patients (%) receiving rescue medication29.211.113.57.38.04.3FPG (mg/dL)Number of patientsn=61n=134n=136n=135n=132n=136Baseline (mean)203195191199191196Change from baseline (adjusted mean)10-9-16-33-32-49Difference from placebo (adjusted mean) (95% CI)---19 (-31, -6)-26 (-38, -14)-43 (-56, -31)-42 (-55, -30)-60 (-72, -47)Figure 1Adjusted Mean Change from Baseline for A1C (%) over 24 Weeks with Linagliptin and Metformin, Alone and in Combination in Patients with Type Diabetes Mellitus Inadequately Controlled with Diet and Exercise FAS completers. Figure 1. Initial Combination Therapy with Linagliptin and Metformin vs Linagliptin in Treatment-Naive PatientsA total of 316 patients with type diabetes diagnosed within the previous 12 months and treatment-naive (no antidiabetic therapy for 12 weeks prior to randomization) and inadequate glycemic control (A1C >=8.5% to <=12.0%) participated in 24-week, randomized, double-blind, study designed to assess the efficacy of linagliptin in combination with metformin vs linagliptin. Patients were randomized (1:1), after 2-week run-in period, to either linagliptin mg plus metformin (1500 to 2000 mg per day, n=159) or linagliptin mg plus placebo, (n=157) administered once daily. Patients in the linagliptin and metformin treatment group were up-titrated to maximum tolerated dose of metformin (1000 to 2000 mg per day) over three-week period.Initial therapy with the combination of linagliptin and metformin provided statistically significant improvements in A1C compared to linagliptin (Table 7). The mean difference between groups in A1C change from baseline was -0.8% with 2-sided 95% confidence interval (-1.23%, -0.45%).Table 7Glycemic Parameters at 24 Weeks in Study Comparing Linagliptin in Combination with Metformin to Linagliptin in Treatment-Naive PatientsLinagliptin mg MetforminLinagliptin mg Placebo+p<0.0001 compared to linagliptin, ++p=0.0054 compared to linagliptinFull analysis set populationA1C: MMRM model included treatment, continuous baseline A1C, baseline A1C by visit interaction, visit by treatment interaction, baseline renal impairment by treatment interaction and baseline renal impairment by treatment by visit interaction. FPG: MMRM model included treatment, continuous baseline A1C, continuous baseline FPG, baseline FPG by visit interaction, visit by treatment interaction, baseline renal impairment by treatment interaction and baseline renal impairment by treatment by visit interaction.A1C (%) Number of patientsn=153n=150Baseline (mean)9.89.9Change from baseline (adjusted mean) -2.9-2Difference from linagliptin (adjusted mean) (95% CI)-0.84+ (-1.23, -0.45)--Patients [n (%)] achieving A1C <7%82 (53.6)45 (30)FPG (mg/dL)Number of patientsn=153n=150Baseline (mean) 196198Change from baseline (adjusted mean) -54-35Difference from linagliptin (adjusted mean) (95% CI)-18++ (-31, -5.5)--The adjusted mean changes for A1C (%) from baseline over time for linagliptin and metformin as compared to linagliptin alone were maintained throughout the 24-week treatment period. Using the completers analysis the respective adjusted means for A1C (%) changes from baseline for linagliptin and metformin as compared to linagliptin alone were -1.9 and -1.3 at week 6, -2.6 and -1.8 at week 12, -2.7 and -1.9 at week 18, and -2.7 and -1.9 at week 24.Changes in body weight from baseline were not clinically significant in either treatment group.. Add-On Combination Therapy with MetforminA total of 701 patients with type diabetes participated in 24-week, randomized, double-blind, placebo-controlled study designed to assess the efficacy of linagliptin in combination with metformin. Patients already on metformin (n=491) at dose of at least 1500 mg per day were randomized after completing 2-week, open-label, placebo run-in period. Patients on metformin and another antihyperglycemic agent (n=207) were randomized after run-in period of approximately weeks on metformin (at dose of at least 1500 mg per day) in monotherapy. Patients were randomized to the addition of either linagliptin mg or placebo, administered once daily. Patients who failed to meet specific glycemic goals during the studies were treated with glimepiride rescue.In combination with metformin, linagliptin provided statistically significant improvements in A1C, FPG, and 2-hour PPG compared with placebo (Table 8). Rescue glycemic therapy was used in 7.8% of patients treated with linagliptin mg and in 18.9% of patients treated with placebo. similar decrease in body weight was observed for both treatment groups.Table 8Glycemic Parameters in Placebo-Controlled Study for Linagliptin in Combination with MetforminLinagliptin mg MetforminPlacebo Metformin Full analysis population using last observation on studyLinagliptin mg Metformin, n=485; Placebo Metformin, n=163HbA1c: ANCOVA model included treatment and number of prior oral OADs as class-effects, as well as baseline HbA1c as continuous covariates. FPG: ANCOVA model included treatment and number of prior OADs as class-effects, as well as baseline HbA1c and baseline FPG as continuous covariates. PPG: ANCOVA model included treatment and number of prior OADs as class-effects, as well as baseline HbA1c and baseline postprandial glucose after two hours as covariate.A1C (%)Number of patientsn=513n=175Baseline (mean)8.18.0Change from baseline (adjusted mean)-0.50.15Difference from placebo metformin (adjusted mean) (95% CI)-0.6 (-0.8, -0.5)--Patients [n (%)] achieving A1C <7%127 (26.2)15 (9.2)FPG (mg/dL)Number of patientsn=495n=159Baseline (mean) 169164Change from baseline (adjusted mean)-1111Difference from placebo metformin (adjusted mean) (95% CI)-21 (-27, -15)--2-hour PPG (mg/dL)Number of patientsn=78n=21Baseline (mean) 270274Change from baseline (adjusted mean)-4918Difference from placebo metformin (adjusted mean) (95% CI)-67 (-95, -40)--. Active-Controlled Study vs Glimepiride in Combination with MetforminThe efficacy of linagliptin was evaluated in 104-week, double-blind, glimepiride-controlled non-inferiority study in type diabetic patients with insufficient glycemic control despite metformin therapy. Patients being treated with metformin only entered run-in period of weeks duration, whereas patients pretreated with metformin and one additional antihyperglycemic agent entered run-in treatment period of weeks duration with metformin monotherapy (dose of >=1500 mg per day) and washout of the other agent. After an additional 2-week placebo run-in period, those with inadequate glycemic control (A1C 6.5% to 10%) were randomized 1:1 to the addition of linagliptin mg once daily or glimepiride. Randomization was stratified by baseline HbA1c (<8.5% vs >=8.5%), and the previous use of antidiabetic drugs (metformin alone vs metformin plus one other OAD). Patients receiving glimepiride were given an initial dose of mg/day and then electively titrated over the next 12 weeks to maximum dose of mg/day as needed to optimize glycemic control. Thereafter, the glimepiride dose was to be kept constant, except for down-titration to prevent hypoglycemia. After 52 weeks and 104 weeks, linagliptin and glimepiride both had reductions from baseline in A1C (52 weeks: -0.4% for linagliptin, -0.6% for glimepiride; 104 weeks: -0.2% for linagliptin, -0.4% for glimepiride) from baseline mean of 7.7% (Table 9). The mean difference between groups in A1C change from baseline was 0.2% with 2-sided 97.5% confidence interval (0.1%, 0.3%) for the intent-to-treat population using last observation carried forward. These results were consistent with the completers analysis.Table 9Glycemic Parameters at 52 and 104 Weeks in Study Comparing Linagliptin to Glimepiride as Add-On Therapy in Patients Inadequately Controlled on MetforminWeek 52Week 104Linagliptin mg MetforminGlimepiride Metformin(mean glimepiride dose mg)Linagliptin mg MetforminGlimepiride Metformin(mean glimepiride dose mg)p<0.0001 vs glimepiride; +p=0.0012 vs glimepirideFull analysis population using last observation on studyHbA1c: ANCOVA model included treatment and number of prior OADs as class-effects, as well as baseline HbA1c as continuous covariates. FPG: ANCOVA model included treatment and number of prior OADs as class-effects, as well as baseline HbA1c and baseline FPG as continuous covariates.A1C (%)Number of patientsn=764n=755n=764 n=755Baseline (mean)7.77.77.77.7Change from baseline (adjusted mean)-0.4-0.6-0.2 -0.4 Difference from glimepiride (adjusted mean) (97.5% CI)0.2 (0.1, 0.3)--0.2 (0.1, 0.3)--FPG (mg/dL)Number of patientsn=733n=725n=733n=725Baseline (mean) 164166164166Change from baseline (adjusted mean)-8-15-2+ -9Patients treated with linagliptin had mean baseline body weight of 86 kg and were observed to have an adjusted mean decrease in body weight of 1.1 kg at 52 weeks and 1.4 kg at 104 weeks. Patients on glimepiride had mean baseline body weight of 87 kg and were observed to have an adjusted mean increase from baseline in body weight of 1.4 kg at 52 weeks and 1.3 kg at 104 weeks (treatment difference p<0.0001 for both timepoints).. Add-On Combination Therapy with Metformin and SulfonylureaA total of 1058 patients with type diabetes mellitus participated in 24-week, randomized, double-blind, placebo-controlled study designed to assess the efficacy of linagliptin in combination with sulfonylurea and metformin. The most common sulfonylureas used by patients in the study were glimepiride (31%), glibenclamide (26%), and gliclazide (26% [not available in the United States]). Patients on sulfonylurea and metformin were randomized to receive linagliptin mg or placebo, each administered once daily. Patients who failed to meet specific glycemic goals during the study were treated with pioglitazone rescue. Glycemic end points measured included A1C and FPG.In combination with sulfonylurea and metformin, linagliptin provided statistically significant improvements in A1C and FPG compared with placebo (Table 10). In the entire study population (patients on linagliptin in combination with sulfonylurea and metformin), mean reduction from baseline relative to placebo in A1C of -0.6% and in FPG of -13 mg/dL was seen. Rescue therapy was used in 5.4% of patients treated with linagliptin mg and in 13% of patients treated with placebo. Change from baseline in body weight did not differ significantly between the groups.Table 10Glycemic Parameters at Final Visit (24-Week Study) for Linagliptin in Combination with Metformin and SulfonylureaLinagliptin mg Metformin SUPlacebo Metformin SUSU=sulfonylureaFull analysis population using last observation on studyLinagliptin mg Metformin SU, n=742; Placebo Metformin SU, n=247HbA1c: ANCOVA model included treatment as class-effects and baseline HbA1c as continuous covariates. FPG: ANCOVA model included treatment as class-effects, as well as baseline HbA1c and baseline FPG as continuous covariates.A1C (%)Number of patientsn=778n=262Baseline (mean)8.28.1Change from baseline (adjusted mean) -0.7-0.1Difference from placebo (adjusted mean) (95% CI)-0.6 (-0.7, -0.5)--Patients [n (%)] achieving A1C <7%217 (29.2)20 (8.1)FPG (mg/dL)Number of patientsn=739n=248Baseline (mean) 159163Change from baseline (adjusted mean)-58Difference from placebo (adjusted mean) (95% CI) -13 (-18, -7)--. 14.2 Linagliptin Cardiovascular Safety Trials. CARMELINAThe cardiovascular risk of linagliptin was evaluated in CARMELINA, multi-national, multi-center, placebo-controlled, double-blind, parallel group trial comparing linagliptin (N=3494) to placebo (N=3485) in adult patients with type diabetes mellitus and history of established macrovascular and/or renal disease. The trial compared the risk of major adverse cardiovascular events (MACE) between linagliptin and placebo when these were added to standard of care treatments for diabetes and other cardiovascular risk factors. The trial was event driven, the median duration of follow-up was 2.2 years and vital status was obtained for 99.7% of patients.Patients were eligible to enter the trial if they were adults with type diabetes, with HbA1c of 6.5% to 10%, and had either albuminuria and previous macrovascular disease (39% of enrolled population), or evidence of impaired renal function by eGFR and Urinary Albumin Creatinine Ratio (UACR) criteria (42% of enrolled population), or both (18% of enrolled population).At baseline the mean age was 66 years and the population was 63% male, 80% Caucasian, 9% Asian, and 6% Black. Mean HbA1c was 8.0% and mean duration of type diabetes mellitus was 15 years. The trial population included 17% patients >=75 years of age and 62% patients with renal impairment defined as eGFR <60 mL/min/1.73 m2. The mean eGFR was 55 mL/min/1.73 m2 and 27% of patients had mild renal impairment (eGFR 60 to 90 mL/min/1.73 m2), 47% of patients had moderate renal impairment (eGFR 30 to <60 mL/min/1.73 m2) and 15% of patients had severe renal impairment (eGFR <30 mL/min/1.73 m2). Patients were taking at least one antidiabetic drug (97%), and the most common were insulin and analogues (57%), metformin (54%) and sulfonylurea (32%). Patients were also taking antihypertensives (96%), lipid lowering drugs (76%) with 72% on statin, and aspirin (62%).The primary endpoint, MACE, was the time to first occurrence of one of three composite outcomes which included cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The study was designed as non-inferiority trial with pre-specified risk margin of 1.3 for the hazard ratio of MACE.The results of CARMELINA, including the contribution of each component to the primary composite endpoint, are shown in Table 11. The estimated hazard ratio for MACE associated with linagliptin relative to placebo was 1.02 with 95% confidence interval of (0.89, 1.17). The upper bound of this confidence interval, 1.17, excluded the risk margin of 1.3. The Kaplan-Meier curve depicting time to first occurrence of MACE is shown in Figure 2.Table 11Major Adverse Cardiovascular Events (MACE) by Treatment Group in the CARMELINA TrialLinagliptin mgn 3494Placebon 3485Hazard RatioNumber of Subjects (%)Incidence Rate per 1000 PYNumber of Subjects (%)Incidence Rate per 1000 PY(95% CI)PY=patient yearsA patient may have experienced more than one component; therefore, the sum of the components is larger than the number of patients who experienced the composite outcome.Composite of first event of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (MACE)434 (12.4)57.7420 (12.1)56.31.02 (0.89, 1.17)CV death255 (7.3)32.6264 (7.6)34.00.96 (0.81, 1.14)Non-fatal MI156 (4.5)20.6135 (3.9)18.01.15 (0.91, 1.45)Non-fatal stroke65 (1.9)8.573 (2.1)9.60.88 (0.63, 1.23)Figure 2Kaplan-Meier: Time to First Occurrence of MACE in the CARMELINA Trial. Figure 2. CAROLINAThe cardiovascular risk of linagliptin was evaluated in CAROLINA, multi-center, multi-national, randomized, double-blind, parallel group trial comparing linagliptin (N=3023) to glimepiride (N=3010) in adult patients with type diabetes mellitus and history of established cardiovascular disease and/or multiple cardiovascular risk factors. The trial compared the risk of major adverse cardiovascular events (MACE) between linagliptin and glimepiride when these were added to standard of care treatments for diabetes and other cardiovascular risk factors. The trial was event driven, the median duration of follow-up was 6.23 years and vital status was obtained for 99.3% of patients.Patients were eligible to enter the trial if they were adults with type diabetes with insufficient glycemic control (defined as HbA1c of 6.5% to 8.5% or 6.5% to 7.5% depending on whether treatment-naive, on monotherapy or on combination therapy), and were defined to be at high cardiovascular risk with previous vascular disease, evidence of vascular related end-organ damage, age >=70 years, and/or two cardiovascular risk factors (duration of diabetes >10 years, systolic blood pressure >140 mmHg, current smoker, LDL cholesterol >=135 mg/dL).At baseline, the mean age was 64 years and the population was 60% male, 73% Caucasian, 18% Asian, and 5% Black. The mean HbA1c was 7.15% and mean duration of type diabetes was 7.6 years. The trial population included 34% patients >=70 years of age and 19% patients with renal impairment defined as eGFR <60 mL/min/1.73 m2. The mean eGFR was 77 mL/min/1.73 m2. Patients were taking at least one antidiabetic drug (91%) and the most common were metformin (83%) and sulfonylurea (28%). Patients were also taking antihypertensives (89%), lipid lowering drugs (70%) with 65% on statin, and aspirin (47%).The primary endpoint, MACE, was the time to first occurrence of one of three composite outcomes which included cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. The study was designed as non-inferiority trial with pre-specified risk margin of 1.3 for the upper bound of the 95% CI for the hazard ratio of MACE.The results of CAROLINA, including the contribution of each component to the primary composite endpoint, are shown in Table 12. The Kaplan-Meier curve depicting time to first occurrence of MACE is shown in Figure 3.Table 12Major Adverse Cardiovascular Events (MACE) by Treatment Group in the CAROLINA StudyLinagliptin mgn=3023Glimepiride (1 mg to mg)n=3010Hazard RatioNumber of Subjects (%)Incidence Rate per 1000 PYNumber of Subjects (%)Incidence Rate per 1000 PY(95% CI)PY=patient yearsA patient may have experienced more than one component; therefore, the sum of the components is larger than the number of patients who experienced the composite outcomeComposite of first event of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (MACE)356 (11.8)20.7362 (12.0)21.20.98 (0.84, 1.14)CV death169 (5.6)9.2168 (5.6)9.21.00 (0.81, 1.24)Non-fatal MI145 (4.8)8.3142 (4.7)8.21.01 (0.80, 1.28)Non-fatal stroke91 (3.0)5.2104 (3.5)6.00.87 (0.66, 1.15)Figure 3Time to First Occurrence of 3P-MACE in CAROLINA. Figure 3.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Individualize the starting dose of JENTADUETO based on the patients current regimen (2.1)The maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin HCl twice daily (2.1)Give twice daily with meals, with gradual dose escalation to reduce the gastrointestinal effects due to metformin (2.1)Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.2)Do not use in patients with eGFR below 30 mL/min/1.73 m2 Initiation is not recommended in patients with eGFR between 30 45 mL/min/1.73 m2 Assess risk/benefit of continuing if eGFR falls below 45 mL/min/1.73 m2 Discontinue if eGFR falls below 30 mL/min/1.73 m2 JENTADUETO may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.3). Individualize the starting dose of JENTADUETO based on the patients current regimen (2.1). The maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin HCl twice daily (2.1). Give twice daily with meals, with gradual dose escalation to reduce the gastrointestinal effects due to metformin (2.1). Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.2)Do not use in patients with eGFR below 30 mL/min/1.73 m2 Initiation is not recommended in patients with eGFR between 30 45 mL/min/1.73 m2 Assess risk/benefit of continuing if eGFR falls below 45 mL/min/1.73 m2 Discontinue if eGFR falls below 30 mL/min/1.73 m2 Do not use in patients with eGFR below 30 mL/min/1.73 m2 Initiation is not recommended in patients with eGFR between 30 45 mL/min/1.73 m2 Assess risk/benefit of continuing if eGFR falls below 45 mL/min/1.73 m2 Discontinue if eGFR falls below 30 mL/min/1.73 m2 JENTADUETO may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.3). 2.1 Recommended Dosing. The dosage of JENTADUETO should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended dose of 2.5 mg linagliptin/1000 mg metformin hydrochloride (HCl) twice daily. JENTADUETO should be given twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with metformin use. For available dosage forms and strengths [see Dosage Forms and Strengths (3)].Recommended starting dose:In patients currently not treated with metformin, initiate treatment with 2.5 mg linagliptin/500 mg metformin HCl twice daily.In patients already treated with metformin, start with 2.5 mg linagliptin and the current dose of metformin HCl taken at each of the two daily meals (e.g., patient on metformin HCl 1000 mg twice daily would be started on 2.5 mg linagliptin/1000 mg metformin HCl twice daily with meals).Patients already treated with linagliptin and metformin individual components may be switched to JENTADUETO containing the same doses of each component.No studies have been performed specifically examining the safety and efficacy of JENTADUETO in patients previously treated with other oral antihyperglycemic agents and switched to JENTADUETO. Any change in therapy of type diabetes mellitus should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.. In patients currently not treated with metformin, initiate treatment with 2.5 mg linagliptin/500 mg metformin HCl twice daily.. In patients already treated with metformin, start with 2.5 mg linagliptin and the current dose of metformin HCl taken at each of the two daily meals (e.g., patient on metformin HCl 1000 mg twice daily would be started on 2.5 mg linagliptin/1000 mg metformin HCl twice daily with meals).. Patients already treated with linagliptin and metformin individual components may be switched to JENTADUETO containing the same doses of each component.. 2.2 Recommended Dosing in Renal Impairment Assess renal function prior to initiation of JENTADUETO and periodically thereafter.JENTADUETO is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2.Initiation of JENTADUETO in patients with an eGFR between 30-45 mL/min/1.73 m2 is not recommended.In patients taking JENTADUETO whose eGFR later falls below 45 mL/min/1.73 m2, assess benefit risk of continuing therapy.Discontinue JENTADUETO if the patients eGFR later falls below 30 mL/min/1.73 m2 [see Contraindications (4) and Warnings and Precautions (5.1)]. 2.3 Discontinuation for Iodinated Contrast Imaging Procedures. Discontinue JENTADUETO at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart JENTADUETO if renal function is stable [see Warnings and Precautions (5.1)].

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Advise the patient to read the FDA-approved patient labeling (Medication Guide). Lactic AcidosisInform patients of the risks of lactic acidosis due to the metformin component, its symptoms, and conditions that predispose to its development [see Warnings and Precautions (5.1)]. Advise patients to discontinue JENTADUETO immediately and to notify their doctor promptly if unexplained hyperventilation, malaise, myalgia, unusual somnolence, slow or irregular heart beat, sensation of feeling cold (especially in the extremities), or other nonspecific symptoms occur. GI symptoms are common during initiation of metformin treatment and may occur during initiation of JENTADUETO therapy; however, advise patients to consult their doctor if they develop unexplained symptoms. Although GI symptoms that occur after stabilization are unlikely to be drug related, such an occurrence of symptoms should be evaluated to determine if it may be due to metformin-induced lactic acidosis or other serious disease.. PancreatitisInform patients that acute pancreatitis has been reported during use of linagliptin. Inform patients that persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting, is the hallmark symptom of acute pancreatitis. Instruct patients to discontinue JENTADUETO promptly and contact their physician if persistent severe abdominal pain occurs [see Warnings and Precautions (5.2)].. Heart FailureInform patients of the signs and symptoms of heart failure. Before initiating JENTADUETO, patients should be asked about history of heart failure or other risk factors for heart failure including moderate to severe renal impairment. Instruct patients to contact their healthcare provider as soon as possible if they experience symptoms of heart failure, including increasing shortness of breath, rapid increase in weight or swelling of the feet [see Warnings and Precautions (5.3)]. Monitoring of Renal FunctionInform patients about the importance of regular testing of renal function and hematological parameters when receiving treatment with JENTADUETO.Instruct patients to inform their doctor that they are taking JENTADUETO prior to any surgical or radiological procedure, as temporary discontinuation of JENTADUETO may be required until renal function has been confirmed to be normal [see Warnings and Precautions (5.1)]. HypoglycemiaInform patients that the risk of hypoglycemia is increased when JENTADUETO is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin, and that lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia [see Warnings and Precautions (5.4)].. Hypersensitivity ReactionsInform patients that serious allergic reactions, such as anaphylaxis, angioedema, and exfoliative skin conditions, have been reported during postmarketing use of linagliptin (one of the components of JENTADUETO). If symptoms of allergic reactions (such as rash, skin flaking or peeling, urticaria, swelling of the skin, or swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing) occur, patients must stop taking JENTADUETO and seek medical advice promptly [see Warnings and Precautions (5.5)].. Alcohol IntakeWarn patients against excessive alcohol intake, either acute or chronic, while receiving JENTADUETO [see Warnings and Precautions (5.1)]. Renal Function and Other Hematologic Parameters MonitoringInform patients that initial and periodic monitoring of hematologic parameters (e.g., hemoglobin/hematocrit and red blood cell indices) and renal function (e.g., eGFR) should be performed, at least on an annual basis [see Warnings and Precautions (5.1, 5.6)].. Severe and Disabling ArthralgiaInform patients that severe and disabling joint pain may occur with this class of drugs. The time to onset of symptoms can range from one day to years. Instruct patients to seek medical advice if severe joint pain occurs [see Warnings and Precautions (5.7)]. Bullous PemphigoidInform patients that bullous pemphigoid has been reported during use of linagliptin. Instruct patients to seek medical advice if blisters or erosions occur [see Warnings and Precautions (5.8)]. PregnancyInform female patients that treatment with metformin may result in an unintended pregnancy in some premenopausal anovulatory females due to its effect on ovulation [see Use in Specific Populations (8.3)].. Missed DoseInstruct patients to take JENTADUETO only as prescribed. If dose is missed, advise patients not to double their next dose.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. JENTADUETOThe results of bioequivalence study in healthy subjects demonstrated that JENTADUETO (linagliptin/metformin hydrochloride) 2.5 mg/500 mg, 2.5 mg/850 mg, and 2.5 mg/1000 mg combination tablets are bioequivalent to coadministration of corresponding doses of linagliptin and metformin as individual tablets. Administration of linagliptin 2.5 mg/metformin hydrochloride 1000 mg fixed-dose combination with food resulted in no change in overall exposure of linagliptin. There was no change in metformin AUC; however, mean peak serum concentration of metformin was decreased by 18% when administered with food. delayed time-to-peak serum concentrations by hours was observed for metformin under fed conditions. These changes are not likely to be clinically significant.. Absorption. LinagliptinThe absolute bioavailability of linagliptin is approximately 30%. Following oral administration, plasma concentrations of linagliptin decline in at least biphasic manner with long terminal half-life (>100 hours), related to the saturable binding of linagliptin to DPP-4. However, the prolonged elimination does not contribute to the accumulation of the drug. The effective half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of linagliptin mg, is approximately 12 hours. After once-daily dosing, steady-state plasma concentrations of linagliptin mg are reached by the third dose, and Cmax and AUC increased by factor of 1.3 at steady-state compared with the first dose. Plasma AUC of linagliptin increased in less than dose-proportional manner in the dose range of to 10 mg. The pharmacokinetics of linagliptin is similar in healthy subjects and in patients with type diabetes. MetforminThe absolute bioavailability of metformin hydrochloride 500 mg tablet given under fasting conditions is approximately 50% to 60%. Studies using single oral doses of metformin tablets 500 mg to 1500 mg, and 850 mg to 2550 mg, indicate that there is lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. Distribution. LinagliptinThe mean apparent volume of distribution at steady-state following single intravenous dose of linagliptin mg to healthy subjects is approximately 1110 L, indicating that linagliptin extensively distributes to the tissues. Plasma protein binding of linagliptin is concentration-dependent decreasing from about 99% at nmol/L to 75% to 89% at >=30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin. At high concentrations, where DPP-4 is fully saturated, 70% to 80% of linagliptin remains bound to plasma proteins and 20% to 30% is unbound in plasma. Plasma binding is not altered in patients with renal or hepatic impairment.. MetforminThe apparent volume of distribution (V/F) of metformin following single oral doses of immediate-release metformin hydrochloride tablets 850 mg averaged 654+-358 L. Metformin is negligibly bound to plasma proteins, in contrast to SUs, which are more than 90% protein bound. Metformin partitions into erythrocytes, most likely as function of time. At usual clinical doses and dosing schedules of metformin tablets, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally <1 mcg/mL. During controlled clinical trials of metformin, maximum metformin plasma levels did not exceed mcg/mL, even at maximum doses.. Elimination. LinagliptinLinagliptin has terminal half-life of about 200 hours at steady-state, though the accumulation half-life is about 11 hours. Renal clearance at steady-state was approximately 70 mL/min.. MetforminMetformin has plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be compartment of distribution.. Metabolism. LinagliptinFollowing oral administration, the majority (about 90%) of linagliptin is excreted unchanged, indicating that metabolism represents minor elimination pathway. small fraction of absorbed linagliptin is metabolized to pharmacologically inactive metabolite, which shows steady-state exposure of 13.3% relative to linagliptin.. MetforminIntravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.. Excretion. LinagliptinFollowing administration of an oral [14C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated via the enterohepatic system (80%) or urine (5%) within days of dosing.. MetforminRenal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be compartment of distribution.. Specific Populations. Renal Impairment JENTADUETO: Studies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in renally impaired patients have not been performed [see Contraindications (4) and Warnings and Precautions (5.1)]. Linagliptin: Under steady-state conditions, linagliptin exposure in patients with mild renal impairment was comparable to healthy subjects. In patients with moderate renal impairment under steady-state conditions, mean exposure of linagliptin increased (AUC,ss by 71% and Cmax by 46%) compared with healthy subjects. This increase was not associated with prolonged accumulation half-life, terminal half-life, or an increased accumulation factor. Renal excretion of linagliptin was below 5% of the administered dose and was not affected by decreased renal function. Patients with type diabetes mellitus and severe renal impairment showed steady-state exposure approximately 40% higher than that of patients with type diabetes mellitus and normal renal function (increase in AUC by 42% and Cmax by 35%). For both type diabetes mellitus groups, renal excretion was below 7% of the administered dose. Metformin: In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased [see Contraindications (4) and Warnings and Precautions (5.1)].. Hepatic Impairment. JENTADUETO: Studies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in hepatically impaired patients have not been performed [see Warnings and Precautions (5.1)].. Linagliptin: In patients with mild hepatic impairment (Child-Pugh class A) steady-state exposure (AUC,ss) of linagliptin was approximately 25% lower and Cmax,ss was approximately 36% lower than in healthy subjects. In patients with moderate hepatic impairment (Child-Pugh class B), AUCss of linagliptin was about 14% lower and Cmax,ss was approximately 8% lower than in healthy subjects. Patients with severe hepatic impairment (Child-Pugh class C) had comparable exposure of linagliptin in terms of AUC0-24 and approximately 23% lower Cmax compared with healthy subjects. Reductions in the pharmacokinetic parameters seen in patients with hepatic impairment did not result in reductions in DPP-4 inhibition.. Metformin hydrochloride: No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment. Body Mass Index (BMI)/Weight. Linagliptin: BMI/Weight had no clinically meaningful effect on the pharmacokinetics of linagliptin based on population pharmacokinetic analysis.. Gender. Linagliptin: Gender had no clinically meaningful effect on the pharmacokinetics of linagliptin based on population pharmacokinetic analysis.. Metformin hydrochloride: Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type diabetes mellitus when analyzed according to gender. Similarly, in controlled clinical studies in patients with type diabetes mellitus, the antihyperglycemic effect of metformin was comparable in males and females.. Geriatric. JENTADUETO: Studies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in geriatric patients have not been performed [see Warnings and Precautions (5.1) and Use in Specific Populations (8.5)]. Linagliptin: Age did not have clinically meaningful impact on the pharmacokinetics of linagliptin based on population pharmacokinetic analysis.. Metformin hydrochloride: Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared with healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by change in renal function.. PediatricStudies characterizing the pharmacokinetics of linagliptin and metformin after administration of JENTADUETO in pediatric patients have not yet been performed.. Race. Linagliptin: Race had no clinically meaningful effect on the pharmacokinetics of linagliptin based on available pharmacokinetic data, including subjects of White, Hispanic, Black, and Asian racial groups.. Metformin hydrochloride: No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type diabetes mellitus, the antihyperglycemic effect was comparable in Caucasians (n=249), Blacks (n=51), and Hispanics (n=24).. Drug InteractionsPharmacokinetic drug interaction studies with JENTADUETO have not been performed; however, such studies have been conducted with the individual components of JENTADUETO (linagliptin and metformin hydrochloride).. Linagliptin. In vitro Assessment of Drug InteractionsLinagliptin is weak to moderate inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes and is not an inducer of CYP isozymes, including CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 4A11.Linagliptin is P-glycoprotein (P-gp) substrate, and inhibits P-gp mediated transport of digoxin at high concentrations. Based on these results and in vivo drug interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates at therapeutic concentrations.. In vivo Assessment of Drug InteractionsStrong inducers of CYP3A4 or P-gp (e.g., rifampin) decrease exposure to linagliptin to subtherapeutic and likely ineffective concentrations [see Drug Interactions (7)]. In vivo studies indicated evidence of low propensity for causing drug interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-gp, and OCT.Table 2Effect of Coadministered Drugs on Systemic Exposure of LinagliptinCoadministered DrugDosing of Coadministered DrugDosing of LinagliptinGeometric Mean Ratio(ratio with/without coadministered drug)No effect=1.0AUC+ Cmax Multiple dose (steady-state) unless otherwise notedFor information regarding clinical recommendations [see Drug Interactions (7.2)]. Single dose+AUC AUC(0 to 24 hours) for single-dose treatments and AUC AUC(TAU) for multiple-dose treatmentsQD=once dailyBID=twice dailyTID=three times dailyMetformin 850 mg TID10 mg QD1.201.03Glyburide1.75 mg mg QD1.021.01Pioglitazone45 mg QD10 mg QD1.131.07Ritonavir200 mg BID5 mg 2.012.96Rifampin600 mg QD5 mg QD0.600.56Table 3Effect of Linagliptin on Systemic Exposure of Coadministered DrugsCoadministered DrugDosing of Coadministered DrugDosing of LinagliptinGeometric Mean Ratio(ratio with/without coadministered drug)No effect=1.0AUC+ Cmax Multiple dose (steady-state) unless otherwise notedSingle dose+AUC AUC(INF) for single-dose treatments and AUC AUC(TAU) for multiple-dose treatmentsAUC=AUC(0-168) and Cmax=Emax for pharmacodynamic end pointsINR=International Normalized RatioPT=Prothrombin TimeQD=once dailyTID=three times dailyMetformin 850 mg TID10 mg QDmetformin1.010.89Glyburide1.75 mg mg QDglyburide0.860.86Pioglitazone45 mg QD10 mg QDpioglitazone0.940.86metabolite M-III0.980.96metabolite M-IV1.041.05Digoxin0.25 mg QD5 mg QDdigoxin1.020.94Simvastatin40 mg QD10 mg QDsimvastatin1.341.10simvastatin acid1.331.21Warfarin10 mg mg QDR-warfarin0.991.00S-warfarin1.031.01INR0.931.04PT1.031.15Ethinylestradiol and levonorgestrelethinylestradiol 0.03 mg and levonorgestrel 0.150 mg QD5 mg QDethinylestradiol1.011.08levonorgestrel1.091.13. Metformin hydrochlorideTable 4Effect of Coadministered Drug on Plasma Metformin Systemic Exposure Coadministered DrugDosing of Coadministered DrugDosing of MetforminGeometric Mean Ratio(ratio with/without coadministered drug)No effect=1.0AUC+ Cmax All metformin and coadministered drugs were given as single doses+AUC=AUC(INF)Ratio of arithmetic meansAt steady-state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC AUC(0-12 hours)Glyburide5 mg850 mgmetformin0.910.93Furosemide40 mg850 mgmetformin1.091.22Nifedipine10 mg850 mgmetformin1.161.21Propranolol40 mg850 mgmetformin0.900.94Ibuprofen400 mg850 mgmetformin1.051.07Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination[see Drug Interactions (7.1)]. Cimetidine400 mg850 mgmetformin1.401.61Carbonic anhydrase inhibitors may cause metabolic acidosis [see Drug Interactions (7.1)].Topiramate100 mg500 mgmetformin1.251.17Table 5Effect of Metformin on Coadministered Drug Systemic ExposureCoadministered DrugDosing of Coadministered DrugDosing of MetforminGeometric Mean Ratio(ratio with/without metformin)No effect=1.0AUC+ Cmax All metformin and coadministered drugs were given as single doses+AUC=AUC(INF) unless otherwise notedRatio of arithmetic means, p-value of difference <0.05AUC(0-24 hours) reportedRatio of arithmetic meansGlyburide5 mg850 mgglyburide0.780.63Furosemide40 mg850 mgfurosemide0.870.69Nifedipine10 mg850 mgnifedipine1.101.08Propranolol40 mg850 mgpropranolol1.011.02Ibuprofen400 mg850 mgibuprofen0.971.01Cimetidine400 mg850 mgcimetidine0.951.01.

SPL MEDGUIDE SECTION.

MEDICATION GUIDEJENTADUETO(R) (JEN ta doo toe)(linagliptin and metformin hydrochloride tablets)for oral useThis Medication Guide has been approved by the U.S. Food and Drug Administration.Revised: March 2020 Read this Medication Guide carefully before you start taking JENTADUETO and each time you get refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. If you have any questions about JENTADUETO, ask your doctor or pharmacist. What is the most important information should know about JENTADUETOJENTADUETO can cause serious side effects, including: 1.Lactic acidosis. Metformin hydrochloride, one of the medicines in JENTADUETO, can cause rare but serious condition called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. Lactic acidosis is medical emergency and must be treated in hospital.Stop taking JENTADUETO and call your doctor right away or go to the nearest hospital emergency room if you get any of the following symptoms of lactic acidosis:feel very weak and tiredhave unusual (not normal) muscle painhave trouble breathinghave unexplained stomach or intestinal problems with nausea and vomiting, or diarrheahave unusual sleepiness or sleep longer than usualfeel cold, especially in your arms and legsfeel dizzy or lightheadedhave slow or irregular heartbeatYou have higher chance of getting lactic acidosis with JENTADUETO if you: have severe kidney problems.have liver problems.drink lot of alcohol (very often or short-term binge drinking).get dehydrated (lose large amount of body fluids). This can happen if you are sick with fever, vomiting, or diarrhea. Dehydration can also happen when you sweat lot with activity or exercise and do not drink enough fluids.have certain x-ray tests with injectable dyes or contrast agents.have surgery or other procedures for which you need to restrict the amount of food and liquid you eat and drink.have congestive heart failure.have heart attack, severe infection, or stroke.are 65 years of age or older.Tell your doctor if you have any of the problems in the list above. Tell your doctor that you are taking JENTADUETO before you have surgery or x-ray tests. Your doctor may decide to stop your JENTADUETO for while if you have surgery or certain x-ray tests. JENTADUETO can have other serious side effects. See What are the possible side effects of JENTADUETO2.Inflammation of the pancreas (pancreatitis) which may be severe and lead to death. Certain medical problems make you more likely to get pancreatitis.Before you start taking JENTADUETO, tell your doctor if you have ever had: inflammation of your pancreas (pancreatitis) history of alcoholism stones in your gallbladder (gallstones) high blood triglyceride levels Stop taking JENTADUETO and call your doctor right away if you have pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.3.Heart failure. Heart failure means your heart does not pump blood well enough.Before you start taking JENTADUETO, tell your doctor if you have ever had heart failure or have problems with your kidneys. Contact your doctor right away if you have any of the following symptoms: increasing shortness of breath or trouble breathing, especially when you lie downswelling or fluid retention, especially in the feet, ankles or legsan unusually fast increase in weightunusual tiredness These may be symptoms of heart failure.What is JENTADUETOJENTADUETO is prescription medicine that contains diabetes medicines, linagliptin (TRADJENTA) and metformin hydrochloride. JENTADUETO can be used along with diet and exercise to lower blood sugar in adults with type diabetes.JENTADUETO is not for people with type diabetes.JENTADUETO is not for people with diabetic ketoacidosis (increased ketones in the blood or urine).If you have had pancreatitis in the past, it is not known if you have higher chance of getting pancreatitis while you take JENTADUETO.It is not known if JENTADUETO is safe and effective in children under 18 years of age.Who should not take JENTADUETODo not take JENTADUETO if you: have severe kidney problems.have condition called metabolic acidosis or diabetic ketoacidosis (increased ketones in the blood or urine).are allergic to linagliptin (TRADJENTA), metformin, or any of the ingredients in JENTADUETO. See the end of this Medication Guide for complete list of ingredients in JENTADUETO.Symptoms of serious allergic reaction to JENTADUETO may include: skin rash, itching, flaking or peelingraised red patches on your skin (hives)swelling of your face, lips, tongue and throat that may cause difficulty in breathing or swallowingdifficulty with swallowing or breathing If you have any of these symptoms, stop taking JENTADUETO and call your doctor right away or go to the nearest hospital emergency room.What should tell my doctor before taking JENTADUETOBefore taking JENTADUETO, tell your doctor about all of your medical conditions, including if you: have or have had inflammation of your pancreas (pancreatitis).have kidney problemshave liver problems.have heart problems, including congestive heart failure.are 65 years of age or older.drink alcohol very often, or drink lot of alcohol in short term (binge drinking).are going to get an injection of dye or contrast agents for an x-ray procedure. JENTADUETO may need to be stopped for short time. Talk to your doctor about when you should stop JENTADUETO and when you should start JENTADUETO again. See What is the most important information should know about JENTADUETO have type diabetes. JENTADUETO should not be used to treat people with type diabetes.have low levels of vitamin B12 in your blood.are pregnant or plan to become pregnant. It is not known if JENTADUETO will harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant. are breastfeeding or plan to breastfeed. JENTADUETO may pass into your breast milk and may harm your baby. Talk with your doctor about the best way to feed your baby if you take JENTADUETO.are woman who has not gone through menopause (premenopausal) who does not have periods regularly or at all. JENTADUETO can cause the release of an egg from an ovary in woman (ovulation). This can increase your chance of getting pregnant. Tell your doctor right away if you become pregnant while taking JENTADUETO.Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. JENTADUETO may affect the way other medicines work, and other medicines may affect how JENTADUETO works.Especially tell your doctor if you take: insulin or other medicines that can lower your blood sugardiuretics (water pills)rifampin (Rifadin, Rimactane, Rifater, Rifamate), an antibiotic that is used to treat tuberculosisKnow the medicines you take. Keep list of them to show your doctor and pharmacist when you get new medicine.How should take JENTADUETOTake JENTADUETO exactly as your doctor tells you to take it.Take JENTADUETO times each day with meals. Taking JENTADUETO with meals may lower your chance of having an upset stomach.If you miss dose, take it with food as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take doses of JENTADUETO at the same time.If you take too much JENTADUETO, call your doctor or local poison control center or go to the nearest hospital emergency room right away.Your doctor may tell you to take JENTADUETO along with other diabetes medicines. Low blood sugar can happen more often when JENTADUETO is taken with certain other diabetes medicines. See What are the possible side effects of JENTADUETOCheck your blood sugar as your doctor tells you to. Your doctor will do blood tests to check how well your kidneys are working before and during your treatment with JENTADUETO.What should avoid while taking JENTADUETOAvoid drinking alcohol very often or drinking lot of alcohol in short period of time (binge drinking). It can increase your chances of getting serious side effects.What are the possible side effects of JENTADUETOJENTADUETO may cause serious side effects, including:See What is the most important information should know about JENTADUETOLow blood sugar (hypoglycemia). If you take JENTADUETO with another medicine that can cause low blood sugar, such as sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take JENTADUETO. Signs and symptoms of low blood sugar may include:headachefast heartbeatirritabilitydizzinessdrowsinesssweatinghungerconfusionweaknessshaking or feeling jitteryAllergic (hypersensitivity) reactions. Serious allergic reactions have happened in people who are taking JENTADUETO. Symptoms may include:swelling of your face, lips, throat, and other areas on your skinraised, red areas on your skin (hives)difficulty with swallowing or breathingskin rash, itching, flaking, or peelingIf you have any of these symptoms, stop taking JENTADUETO and call your doctor right away or go to the nearest hospital emergency room.Low vitamin B12 (vitamin B12 deficiency). Using metformin for long periods of time may cause decrease in the amount of vitamin B12 in your blood, especially if you have had low vitamin B12 blood levels before. Your doctor may do blood tests to check your vitamin B12 levels.Joint pain. Some people who take medicines called DPP-4 inhibitors, one of the medicines in JENTADUETO, may develop joint pain that can be severe. Call your doctor if you have severe joint pain.Skin reaction. Some people who take medicines called DPP-4 inhibitors, one of the medicines in JENTADUETO, may develop skin reaction called bullous pemphigoid that can require treatment in hospital. Tell your doctor right away if you develop blisters or the breakdown of the outer layer of your skin (erosion). Your doctor may tell you to stop taking JENTADUETO.The most common side effects of JENTADUETO include stuffy or runny nose and sore throat and diarrhea.Tell your doctor if you have any side effects that bother you or that do not go away.These are not all the possible side effects of JENTADUETO. For more information, ask your doctor or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should store JENTADUETOStore JENTADUETO at room temperature between 68F and 77F (20C and 25C). Keep tablets dry. Keep JENTADUETO and all medicines out of the reach of children.General information about the safe and effective use of JENTADUETO.Medicines are sometimes prescribed for purposes other than those listed in Medication Guide. Do not use JENTADUETO for condition for which it was not prescribed. Do not give JENTADUETO to other people, even if they have the same symptoms you have. It may harm them.You can ask your pharmacist or doctor for information about JENTADUETO that is written for health professionals. What are the ingredients in JENTADUETOActive Ingredients: linagliptin and metformin hydrochlorideInactive Ingredients: arginine, corn starch, copovidone, colloidal silicon dioxide, magnesium stearate, titanium dioxide, propylene glycol, hypromellose, talc2.5 mg/500 mg and 2.5 mg/850 mg tablets also contain yellow ferric oxide. 2.5 mg/850 mg and 2.5 mg/1000 mg tablets also contain red ferric oxide.Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA.Licensed from: Boehringer Ingelheim International GmbH, Ingelheim, Germany.The other brands listed are trademarks of their respective owners and are not trademarks of Boehringer Ingelheim Pharmaceuticals, Inc.JENTADUETO is registered trademark of and used under license from Boehringer Ingelheim International GmbHBoehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the CARMELINA(R) and CAROLINA(R) trademarks under license.Copyright (C) 2020 Boehringer Ingelheim International GmbH ALL RIGHTS RESERVEDIT6841IC312020For more information about JENTADUETO, including current prescribing information and Medication Guide, go to www.JENTADUETO.com, or scan the code below, or call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257, or (TTY) 1-800-459-9906.. 1.Lactic acidosis. Metformin hydrochloride, one of the medicines in JENTADUETO, can cause rare but serious condition called lactic acidosis (a build-up of lactic acid in the blood) that can cause death. Lactic acidosis is medical emergency and must be treated in hospital.Stop taking JENTADUETO and call your doctor right away or go to the nearest hospital emergency room if you get any of the following symptoms of lactic acidosis:. feel very weak and tired. have unusual (not normal) muscle pain. have trouble breathing. have unexplained stomach or intestinal problems with nausea and vomiting, or diarrhea. have unusual sleepiness or sleep longer than usual. feel cold, especially in your arms and legs. feel dizzy or lightheaded. have slow or irregular heartbeat. have severe kidney problems.. have liver problems.. drink lot of alcohol (very often or short-term binge drinking).. get dehydrated (lose large amount of body fluids). This can happen if you are sick with fever, vomiting, or diarrhea. Dehydration can also happen when you sweat lot with activity or exercise and do not drink enough fluids.. have certain x-ray tests with injectable dyes or contrast agents.. have surgery or other procedures for which you need to restrict the amount of food and liquid you eat and drink.. have congestive heart failure.. have heart attack, severe infection, or stroke.. are 65 years of age or older.. 2.Inflammation of the pancreas (pancreatitis) which may be severe and lead to death. Certain medical problems make you more likely to get pancreatitis.. inflammation of your pancreas (pancreatitis) a history of alcoholism stones in your gallbladder (gallstones) high blood triglyceride levels 3.Heart failure. Heart failure means your heart does not pump blood well enough.. increasing shortness of breath or trouble breathing, especially when you lie down. swelling or fluid retention, especially in the feet, ankles or legs. an unusually fast increase in weight. unusual tiredness JENTADUETO is prescription medicine that contains diabetes medicines, linagliptin (TRADJENTA) and metformin hydrochloride. JENTADUETO can be used along with diet and exercise to lower blood sugar in adults with type diabetes.. JENTADUETO is not for people with type diabetes.. JENTADUETO is not for people with diabetic ketoacidosis (increased ketones in the blood or urine).. If you have had pancreatitis in the past, it is not known if you have higher chance of getting pancreatitis while you take JENTADUETO.. It is not known if JENTADUETO is safe and effective in children under 18 years of age.. have severe kidney problems.. have condition called metabolic acidosis or diabetic ketoacidosis (increased ketones in the blood or urine).. are allergic to linagliptin (TRADJENTA), metformin, or any of the ingredients in JENTADUETO. See the end of this Medication Guide for complete list of ingredients in JENTADUETO.Symptoms of serious allergic reaction to JENTADUETO may include: skin rash, itching, flaking or peelingraised red patches on your skin (hives)swelling of your face, lips, tongue and throat that may cause difficulty in breathing or swallowingdifficulty with swallowing or breathing If you have any of these symptoms, stop taking JENTADUETO and call your doctor right away or go to the nearest hospital emergency room.. skin rash, itching, flaking or peeling. raised red patches on your skin (hives). swelling of your face, lips, tongue and throat that may cause difficulty in breathing or swallowing. difficulty with swallowing or breathing. have or have had inflammation of your pancreas (pancreatitis).. have kidney problems. have liver problems.. have heart problems, including congestive heart failure.. are 65 years of age or older.. drink alcohol very often, or drink lot of alcohol in short term (binge drinking).. are going to get an injection of dye or contrast agents for an x-ray procedure. JENTADUETO may need to be stopped for short time. Talk to your doctor about when you should stop JENTADUETO and when you should start JENTADUETO again. See What is the most important information should know about JENTADUETO have type diabetes. JENTADUETO should not be used to treat people with type diabetes.. have low levels of vitamin B12 in your blood.. are pregnant or plan to become pregnant. It is not known if JENTADUETO will harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant. are breastfeeding or plan to breastfeed. JENTADUETO may pass into your breast milk and may harm your baby. Talk with your doctor about the best way to feed your baby if you take JENTADUETO.. are woman who has not gone through menopause (premenopausal) who does not have periods regularly or at all. JENTADUETO can cause the release of an egg from an ovary in woman (ovulation). This can increase your chance of getting pregnant. Tell your doctor right away if you become pregnant while taking JENTADUETO.. insulin or other medicines that can lower your blood sugar. diuretics (water pills). rifampin (Rifadin, Rimactane, Rifater, Rifamate), an antibiotic that is used to treat tuberculosis. Take JENTADUETO exactly as your doctor tells you to take it.. Take JENTADUETO times each day with meals. Taking JENTADUETO with meals may lower your chance of having an upset stomach.. If you miss dose, take it with food as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. Do not take doses of JENTADUETO at the same time.. If you take too much JENTADUETO, call your doctor or local poison control center or go to the nearest hospital emergency room right away.. Your doctor may tell you to take JENTADUETO along with other diabetes medicines. Low blood sugar can happen more often when JENTADUETO is taken with certain other diabetes medicines. See What are the possible side effects of JENTADUETO. Check your blood sugar as your doctor tells you to. Your doctor will do blood tests to check how well your kidneys are working before and during your treatment with JENTADUETO.. See What is the most important information should know about JENTADUETO. Low blood sugar (hypoglycemia). If you take JENTADUETO with another medicine that can cause low blood sugar, such as sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take JENTADUETO. Signs and symptoms of low blood sugar may include:. headache. fast heartbeat. irritability. dizziness. drowsiness. sweating. hunger. confusion. weakness. shaking or feeling jittery. Allergic (hypersensitivity) reactions. Serious allergic reactions have happened in people who are taking JENTADUETO. Symptoms may include:. swelling of your face, lips, throat, and other areas on your skin. raised, red areas on your skin (hives). difficulty with swallowing or breathing. skin rash, itching, flaking, or peeling. Low vitamin B12 (vitamin B12 deficiency). Using metformin for long periods of time may cause decrease in the amount of vitamin B12 in your blood, especially if you have had low vitamin B12 blood levels before. Your doctor may do blood tests to check your vitamin B12 levels.. Joint pain. Some people who take medicines called DPP-4 inhibitors, one of the medicines in JENTADUETO, may develop joint pain that can be severe. Call your doctor if you have severe joint pain.. Skin reaction. Some people who take medicines called DPP-4 inhibitors, one of the medicines in JENTADUETO, may develop skin reaction called bullous pemphigoid that can require treatment in hospital. Tell your doctor right away if you develop blisters or the breakdown of the outer layer of your skin (erosion). Your doctor may tell you to stop taking JENTADUETO.. Store JENTADUETO at room temperature between 68F and 77F (20C and 25C). Keep tablets dry. Image.

CLINICAL TRIALS EXPERIENCE SECTION.

6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.. Linagliptin/MetforminThe safety of concomitantly administered linagliptin (daily dose mg) and metformin (mean daily dose of approximately 1800 mg) has been evaluated in 2816 patients with type diabetes mellitus treated for >=12 weeks in clinical trials.Three placebo-controlled studies with linagliptin metformin were conducted: studies were 24 weeks in duration, study was 12 weeks in duration. In the placebo-controlled clinical studies, adverse reactions which occurred in >=5% of patients receiving linagliptin metformin (n=875) and were more common than in patients given placebo metformin (n=539) included nasopharyngitis (5.7% vs 4.3%).In 24-week factorial design study, adverse reactions reported in >=5% of patients receiving linagliptin metformin and were more common than in patients given placebo are shown in Table 1.Table 1Adverse Reactions Reported in >=5% of Patients Treated with Linagliptin Metformin and Greater than with Placebo in 24-week Factorial-Design StudyAdverse ReactionsPlacebo (%) n=72Linagliptin Monotherapy (%) n=142Metformin Monotherapy (%) n=291Combination of Linagliptin with Metformin (%) n=286Nasopharyngitis1.45.62.76.3Diarrhea2.83.53.86.3Other adverse reactions reported in clinical studies with treatment of linagliptin metformin were hypersensitivity (e.g., urticaria, angioedema, or bronchial hyperreactivity), cough, decreased appetite, nausea, vomiting, pruritus, and pancreatitis.. LinagliptinAdverse reactions reported in >=2% of patients treated with linagliptin mg and more commonly than in patients treated with placebo included: nasopharyngitis (7.0% vs 6.1%), diarrhea (3.3% vs 3.0%), and cough (2.1% vs 1.4%).Rates for other adverse reactions for linagliptin mg vs placebo when linagliptin was used in combination with specific anti-diabetic agents were: urinary tract infection (3.1% vs 0%) and hypertriglyceridemia (2.4% vs 0%) when linagliptin was used as add-on to sulfonylurea; hyperlipidemia (2.7% vs 0.8%) and weight increased (2.3% vs 0.8%) when linagliptin was used as add-on to pioglitazone; and constipation (2.1% vs 1%) when linagliptin was used as add-on to basal insulin therapy.Other adverse reactions reported in clinical studies with treatment of linagliptin monotherapy were hypersensitivity (e.g., urticaria, angioedema, localized skin exfoliation, or bronchial hyperreactivity) and myalgia. In the clinical trial program, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure while being treated with linagliptin compared with 3.7 cases per 10,000 patient year exposure while being treated with comparator (placebo and active comparator, sulfonylurea). Three additional cases of pancreatitis were reported following the last administered dose of linagliptin.. MetforminThe most common (>5%) established adverse reactions due to initiation of metformin therapy are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache.. Hypoglycemia. Linagliptin/MetforminIn 24-week factorial design study, hypoglycemia was reported in (1.4%) of 286 subjects treated with linagliptin metformin, (2.1%) of 291 subjects treated with metformin, and (1.4%) of 72 subjects treated with placebo. The incidence of hypoglycemia with plasma glucose <54 mg/dL was 8.1% in the linagliptin group (N=792) compared to 5.3% in the placebo group (N=263) when administered in combination with metformin and sulfonylurea in 24-week study.. LinagliptinThe incidence of severe hypoglycemia (requiring assistance) was 1.7% in the linagliptin group (N=631) compared to 1.1% in the placebo group (N=630) when administered in combination with basal insulin in 52-week study.. Laboratory Tests. Linagliptin. Increase in Uric Acid: Changes in laboratory values that occurred more frequently in the linagliptin group and >=1% more than in the placebo group were increases in uric acid (1.3% in the placebo group, 2.7% in the linagliptin group).. Increase in Lipase: In placebo-controlled clinical trial with linagliptin in type diabetes mellitus patients with micro- or macroalbuminuria, mean increase of 30% in lipase concentrations from baseline to 24 weeks was observed in the linagliptin arm compared to mean decrease of 2% in the placebo arm. Lipase levels above times upper limit of normal were seen in 8.2% compared to 1.7% patients in the linagliptin and placebo arms, respectively.. Increase in Amylase: In cardiovascular safety study comparing linagliptin versus glimepiride in patients with type diabetes mellitus, amylase levels above times upper limit of normal were seen in 1.0% compared to 0.5% of patients in the linagliptin and glimepiride arms, respectively.The clinical significance of elevations in lipase and amylase with linagliptin is unknown in the absence of potential signs and symptoms of pancreatitis [see Warnings and Precautions (5.2)]. Metformin. Decrease in Vitamin B12 In metformin clinical trials of 29-week duration, decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients.